---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-090853"
form_type: "8-K/A"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2023-04-04T23:59:59+00:00"
generated_at: "2026-06-17T06:27:59.397376+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CalciMedica files audited FY2022 financials post-reverse merger; net loss $14.5M

## Summary
- Net loss of $14.5M in 2022, accumulated deficit $118.4M as of Dec 31, 2022.
- Cash and cash equivalents $1.3M at year-end 2022; merger and private placement raised ~$34.2M in March 2023.
- Reverse merger closed March 20, 2023; Graybug Vision renamed CalciMedica, surviving as public entity.
- Former CalciMedica stockholders own ~72% of combined company on fully diluted basis.
- Going concern opinion included; management expects new funds to support operations beyond 12 months.

## SEC filing metadata
- accession: 0001193125-23-090853
- form_type: 8-K/A
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2023-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312523090853/0001193125-23-090853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312523090853/d471673d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-090853
- JSON: https://secwatch.observer/filing/0001193125-23-090853.json
- Plain text: https://secwatch.observer/filing/0001193125-23-090853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.